MX2022013301A - Métodos y composiciones para tratar las afecciones inflamatorias asociadas con una enfermedad infecciosa. - Google Patents

Métodos y composiciones para tratar las afecciones inflamatorias asociadas con una enfermedad infecciosa.

Info

Publication number
MX2022013301A
MX2022013301A MX2022013301A MX2022013301A MX2022013301A MX 2022013301 A MX2022013301 A MX 2022013301A MX 2022013301 A MX2022013301 A MX 2022013301A MX 2022013301 A MX2022013301 A MX 2022013301A MX 2022013301 A MX2022013301 A MX 2022013301A
Authority
MX
Mexico
Prior art keywords
compositions
conditions associated
methods
infectious disease
inflammatory conditions
Prior art date
Application number
MX2022013301A
Other languages
English (en)
Inventor
Timothy Alexander Moseley
Kenneth Allen Pettine
Kevin Hicok
Original Assignee
Direct Biologics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Direct Biologics Llc filed Critical Direct Biologics Llc
Publication of MX2022013301A publication Critical patent/MX2022013301A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/366—Thrombomodulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Endocrinology (AREA)
  • Dispersion Chemistry (AREA)

Abstract

Se divulgan en la presente composiciones que comprenden una preparación de células madre mesenquimales (MSC) y una o más biomoléculas y el uso de dichas composiciones para el tratamiento de una infección microbiana o los síntomas o las afecciones patológicas secundarias asociados con dicha infección.
MX2022013301A 2020-04-22 2021-04-22 Métodos y composiciones para tratar las afecciones inflamatorias asociadas con una enfermedad infecciosa. MX2022013301A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063013865P 2020-04-22 2020-04-22
US202063198706P 2020-11-06 2020-11-06
PCT/US2021/028686 WO2021216903A1 (en) 2020-04-22 2021-04-22 Methods and compositions for treating inflammatory conditions associated with infectious disease

Publications (1)

Publication Number Publication Date
MX2022013301A true MX2022013301A (es) 2023-02-14

Family

ID=78270105

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013301A MX2022013301A (es) 2020-04-22 2021-04-22 Métodos y composiciones para tratar las afecciones inflamatorias asociadas con una enfermedad infecciosa.

Country Status (11)

Country Link
US (1) US12570980B2 (es)
EP (1) EP4138867A4 (es)
JP (1) JP2023523588A (es)
KR (1) KR20230004709A (es)
CN (1) CN115843253A (es)
AU (2) AU2021261384B2 (es)
BR (1) BR112022021445A2 (es)
CA (1) CA3180973A1 (es)
IL (1) IL297563A (es)
MX (1) MX2022013301A (es)
WO (1) WO2021216903A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12453743B2 (en) 2018-05-30 2025-10-28 Direct Biologics, Llc Mesenchymal stem cell (MSC) growth factor and extracellular vesicle preparation in frozen or powdered form and methods of use
EP3920946A4 (en) 2019-02-07 2022-11-09 Direct Biologics LLC METHOD FOR TREATING OSTEOARTHRITIS USING A COMBINATION OF EXOSOMES OF MESENCHYMATE STEM CELLS, SYNOVIAL MESENCHYMATE STEM CELLS AND SCAFFOLDS
EP3999083A4 (en) 2019-07-18 2023-07-26 Direct Biologics LLC Preparations comprising mesenchymal stem cells and cannabinoids and methods of their use
MX2022013301A (es) 2020-04-22 2023-02-14 Direct Biologics Llc Métodos y composiciones para tratar las afecciones inflamatorias asociadas con una enfermedad infecciosa.
KR102317052B1 (ko) * 2020-05-04 2021-10-25 주식회사 티에스셀바이오 태반 유래의 세포외 소포의 항염증 항바이러스 효과 조성물
CN113789333B (zh) * 2021-09-07 2023-07-14 中国人民解放军军事科学院军事医学研究院 Chi3l1在调控hUC-MSCs抑制Th17分化介导的免疫调节作用上的应用
CN118414437A (zh) 2021-12-21 2024-07-30 学校法人关西医科大学 结核感染试样的筛选方法和用于该方法的探针组
CN114469996B (zh) * 2021-12-23 2023-10-20 中国医学科学院医学生物学研究所 一种包含miR-135b-5p的外泌体及在抗轮状病毒感染中的应用
JP2025511272A (ja) * 2022-03-29 2025-04-15 ダイレクト バイオロジクス エルエルシー Ｒｎａを含むセクレトームおよびその使用方法
CN115478117A (zh) * 2022-05-11 2022-12-16 江苏命码生物科技有限公司 一种用于早期预警新型冠状病毒中重型、危重型病例的试剂盒
US11878036B2 (en) 2022-05-25 2024-01-23 Neuvian LLC Vaginal care compositions and methods of improving vaginal health
JP7406059B1 (ja) * 2022-10-20 2023-12-27 防衛装備庁長官 急性ストレス評価用データの生成方法
CN116656699B (zh) * 2023-05-16 2024-05-31 南京农业大学 SESN2和chi-miR-130b-3p在调节由玉米赤霉烯酮诱导的颗粒细胞凋亡中的应用
US12502407B2 (en) 2024-04-25 2025-12-23 Direct Biologics, Llc Treatment of fistula with bone marrow mesenchymal stem cell derived extracellular vesicles
CN118459570B (zh) * 2024-07-10 2024-11-12 南京领源生物科技有限公司 一种能改善胰岛素分泌和增殖功能的多肽pdmhs2

Family Cites Families (209)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1601438A (es) 1968-10-17 1970-08-24
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
CA2018228C (en) 1989-06-05 1996-02-27 Nancy L. Parenteau Cell culture systems and media
US5135917A (en) 1990-07-12 1992-08-04 Nova Pharmaceutical Corporation Interleukin receptor expression inhibiting antisense oligonucleotides
DE69922933T2 (de) 1998-03-13 2005-12-29 Osiris Therapeutics, Inc. Anwendungen für humane nicht autologe, mesenchymale stammzellen
GB9807639D0 (en) 1998-04-14 1998-06-10 Kennedy Rheumatology Inst Anti-inflammatory agents
FR2785543B1 (fr) 1998-11-05 2003-02-28 Inst Nat Sante Rech Med Exosomes modifies et utilisations
US6372494B1 (en) 1999-05-14 2002-04-16 Advanced Tissue Sciences, Inc. Methods of making conditioned cell culture medium compositions
US7311905B2 (en) 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
WO2003051331A1 (en) 2001-10-26 2003-06-26 Baranowitz Steven A Methods for treating wounds using melanin and related substances
DE10224982A1 (de) 2002-06-05 2003-12-24 Rolf Hoffmann Mesenchymale Stammzellen des Haarfollikels und deren Verwendung
US20040248970A1 (en) 2003-04-10 2004-12-09 Webster G.R. Barrie CBD-delta8-THC composition
CA2530732C (en) 2003-06-27 2015-03-31 DePuy Synthes Products, Inc. Regeneration and repair of neural tissue using postpartum-derived cells
WO2006036213A2 (en) 2004-04-29 2006-04-06 Pediamed Pharmaceuticals, Inc. The use of gammaglobulin for the treatment of periodontal disease
KR100668371B1 (ko) 2004-12-30 2007-01-12 한훈 제대혈 유래 줄기세포를 이용한 대머리 치료
US20080241112A1 (en) 2005-05-10 2008-10-02 Christof Westenfelder Therapy of Kidney Diseases and Multiorgan Failure with Mesenchymal Stem Cells and Mesenchymal Stem Cell Conditioned Media
EP1977758B1 (en) 2005-08-19 2011-02-23 Duke University STEM CELL DERIVED PARACRINE FACTOR Sfrp1 FOR USE IN REDUCING CELL DEATH IN CARDIAC TISSUE
US20070254827A1 (en) 2006-04-27 2007-11-01 The Regents Of The University Of California Alpha-aminobenzyl-alpha,alpha,-diphosphoric acid selective chelation of beryllium
US20090304644A1 (en) 2006-05-30 2009-12-10 Cytori Therapeutics, Inc. Systems and methods for manipulation of regenerative cells separated and concentrated from adipose tissue
US8372797B2 (en) 2006-06-22 2013-02-12 Creative Medical Health, Inc. Treatment of erectile dysfunction by stem cell therapy
WO2008023829A1 (en) 2006-08-22 2008-02-28 National University Corporation Tokyo Medical And Dental University Application of synovium-derived mesenchymal stem cells (mscs) for cartilage or meniscus regeneration
US8021882B2 (en) 2006-08-24 2011-09-20 Johnstone Brian H Production of neural protective and regenerative factors from stem cells and treatment of nervous system conditions therewith
CA2711218C (en) 2008-01-04 2019-08-06 Lydac Neuroscience Limited A method of producing a population of differentiated cells
US20090177487A1 (en) 2008-01-07 2009-07-09 Tera Eerkes Methods for Assessing Genetic Compatibility
JP5718648B2 (ja) 2008-02-22 2015-05-13 エイジェンシー・フォー・サイエンス，テクノロジー・アンド・リサーチ（エイ・スター） 間葉系幹細胞粒子
BRPI0909866B1 (pt) 2008-06-11 2021-08-24 Fresenius Medical Care Deutschland Gmbh Método de produção de um meio condicionado de células progenitoras de fígado, meio condicionado e composição farmacêutica
US20120114618A1 (en) 2009-03-26 2012-05-10 The Regents Of The University Of California Mesenchymal Stem Cells Producing Inhibitory RNA for Disease Modification
WO2010139424A1 (de) 2009-06-05 2010-12-09 Skinrephair Ltd. Verwendung von stammzellen aus haarwurzelscheiden und keratinozytenvorläuferzellen zur regeneration gealterter haut
EP2470164B1 (en) 2009-08-27 2017-05-31 Technion Research & Development Foundation Ltd. Liposomal compositions and uses of same
EP2533859B1 (en) 2010-02-10 2016-04-06 Nayacure Therapeutics Ltd Pharmaceutical compositions for the treatment and prevention of cancer
KR20130008594A (ko) 2010-03-26 2013-01-22 고쿠리츠 다이가쿠 호우징 나고야 다이가쿠 손상부 치료용 조성물
ES2667532T3 (es) 2010-06-18 2018-05-11 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Neogénesis del folículo piloso
PT3470057T (pt) 2010-09-29 2021-12-03 Pulmatrix Operating Co Inc Pós secos catiónicos compreendendo sais de magnésio
HUE045869T2 (hu) 2010-11-02 2020-01-28 Univ Columbia Módszerek hajhullásos rendellenességek kezelésére
US20140004601A1 (en) 2010-12-20 2014-01-02 Agency For Science, Technology And Research Method of purifying exosomes
CN103648509B (zh) 2011-03-11 2019-02-22 儿童医学中心公司 与间充质干细胞外来体相关的方法和组合物
US9623051B2 (en) 2011-04-15 2017-04-18 The Regents Of The University Of California Decellularized extracellular matrix
CA2839530A1 (en) 2011-06-16 2012-12-20 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Biomarker compositions and methods
US8494123B2 (en) 2011-07-01 2013-07-23 Apple Inc. On-hold visual menu from a user's communications device
ITRM20110403A1 (it) 2011-07-28 2013-01-29 Ospedale Pediatrico Bambino Gesu Microvescicole isolate da cellule mesenchimali come agenti immunosoppressori.
WO2013060899A2 (en) 2011-10-27 2013-05-02 Universität Leipzig Method for deriving melanocytes from the hair follicle outer root sheath and preparation for grafting
EP2776578A1 (en) 2011-11-09 2014-09-17 Allocure, Inc. Assay for the prediction of therapeutic effectiveness or potency of mesenchymal stem cells, and methods of using same
EP3336190B1 (en) 2011-12-13 2021-02-24 Henry Ford Health System Methods, systems, and compositions for cell-derived/vesicle-based microrna delivery
US9427450B2 (en) 2012-01-31 2016-08-30 Xon Cells, Inc. Therapeutic immune modulation by stem cell secreted exosomes
EP2822659A2 (en) 2012-03-07 2015-01-14 Fibrocell Technologies, Inc. Topical dermal formulations and methods of personalized treatment of skin
CA2868506C (en) 2012-04-03 2023-10-24 Reneuron Limited Stem cell microparticles
HK1211316A1 (en) 2012-04-20 2016-05-20 艾珀特玛治疗公司 Mirna modulators of thermogenesis
EP2850178A4 (en) 2012-05-18 2015-10-28 Agency Science Tech & Res EXOSOMES OF MESHCHYMIC STROKE CELL OF UMBILICAL CORD
US20150150954A1 (en) 2012-07-04 2015-06-04 The University Of Sydney Treatment of inflammatory skin disorders
EP2687219A1 (en) 2012-07-18 2014-01-22 Universität Duisburg-Essen Use of preparations comprising exosomes derived from mesenchymal stem cells (MSCs) in the prevention and therapy of inflammatory conditions
KR20150059168A (ko) 2012-07-19 2015-05-29 레뉴런 리미티드 줄기 세포 마이크로입자
CU24121B1 (es) 2012-08-02 2015-08-27 Ct De Ingeniería Genética Y Biotecnología Vesículas que comprenden factor de crecimiento epidérmico y composiciones que las contienen
EP3563859B1 (en) 2012-08-13 2021-10-13 Cedars-Sinai Medical Center Cardiosphere-derived exosomes for tissue regeneration
EP2929035A1 (en) 2012-12-07 2015-10-14 Shire Human Genetic Therapies, Inc. Lipidic nanoparticles for mrna delivering
US9408874B2 (en) 2013-02-15 2016-08-09 Kenneth Allen Pettine Regenerative autologous bone marrow cell therapies and methods for their use in the treatment of joint pain
WO2015031110A2 (en) 2013-08-27 2015-03-05 The Regents Of The University Of California Combination therapy to promote wound healing
AU2014331523B2 (en) 2013-10-04 2020-10-01 Cell Ideas Pty Ltd Biomarkers for cell therapy
GB2520300A (en) 2013-11-15 2015-05-20 Univ Loughborough Cell Culture System
US20170051359A1 (en) 2014-05-01 2017-02-23 Stichting Vumc SMALL ncRNAS AS BIOMARKERS
US20170304368A1 (en) 2014-10-06 2017-10-26 Cedars-Sinai Medical Center Polarization of macrophages to a healing phenotype by cardiosphere-derived cells and by the exosomes secreted by such cells
WO2016082882A1 (en) 2014-11-27 2016-06-02 Med Cell Europe Ag Secretomes and method for producing secretomes
RU2644650C2 (ru) 2014-12-01 2018-02-13 Общество с ограниченной ответственностью "Т-Хелпер Клеточные Технологии" Материал стволовых клеток и способ его получения
CN104622904A (zh) 2015-02-05 2015-05-20 山西医科大学 一种皮肤干细胞活性成分及其应用
CA3017571A1 (en) 2015-03-16 2016-09-22 Duncan Ross Method of treatment comprising membrane-enclosed vesicle
GB201505747D0 (en) 2015-04-02 2015-05-20 Univ Bristol Exosomes
WO2016170348A2 (en) 2015-04-22 2016-10-27 Mina Therapeutics Limited Sarna compositions and methods of use
WO2016182959A1 (en) 2015-05-11 2016-11-17 Editas Medicine, Inc. Optimized crispr/cas9 systems and methods for gene editing in stem cells
WO2017001649A1 (en) 2015-07-02 2017-01-05 Med Cell Europe Ag Secretomes and method for producing secretomes
CN111150743A (zh) 2018-11-06 2020-05-15 中国医药大学 间质干细胞在治疗多发性硬化症的用途
EP3328413B1 (en) 2015-07-29 2024-09-04 Indiana University Research and Technology Corporation Materials and methods for treating and evaluating ischemic and/or reperfusion-injured tissue and/or tissue susceptible to same
CA2993224A1 (en) 2015-07-31 2017-02-09 Zen-Bio, Inc. Exosome compositions and use thereof for soft tissue repair
US10760053B2 (en) 2015-10-15 2020-09-01 StemoniX Inc. Method of manufacturing or differentiating mammalian pluripotent stem cells or progenitor cells using a hollow fiber bioreactor
KR102311832B1 (ko) 2015-10-16 2021-10-13 (주)프로스테믹스 줄기세포 유래 엑소좀을 포함하는 상처 치료, 피부 개선 및 탈모 방지 또는 치료용 조성물 및 그 제조방법
KR101765767B1 (ko) 2015-11-02 2017-08-07 희성촉매 주식회사 담체 계면 공극 집중 매몰형 scr 촉매 구조체
US20170121685A1 (en) 2015-11-02 2017-05-04 Tigenix S.A.U. Mesenchymal stem cell-derived exosomes and their uses
AU2016381513A1 (en) 2015-12-30 2018-07-19 The Regents Of The University Of California Methods for enhanced production and isolation of cell-derived vesicles
WO2017123022A1 (ko) 2016-01-12 2017-07-20 주식회사 강스템바이오텍 고함량의 성장인자를 함유한 줄기세포 유래 엑소좀
EP3922253A1 (en) 2016-01-15 2021-12-15 Orbsen Therapeutics Limited Sdc-2 exosome compositions and methods of isolation and use
EP3414320A1 (en) 2016-02-12 2018-12-19 Cell Care Therapeutics Adipose tissue derived mesenchymal stromal cell conditioned media and methods of making and using the same
EP3423158B1 (en) 2016-02-24 2023-11-15 The Rockefeller University Embryonic cell-based therapeutic candidate screening systems, models for huntington's disease and uses thereof
US20190000886A1 (en) * 2016-03-16 2019-01-03 Duncan ROSS Method of treatment of osteochondral defects
JP2017180553A (ja) 2016-03-29 2017-10-05 トヨタ自動車株式会社 動力伝達装置
US10792411B2 (en) 2016-05-09 2020-10-06 Jae-Hyung Robert CHANG Accelerated method for preparing platelet rich plasma
RU2708329C2 (ru) 2016-05-31 2019-12-05 Общество с ограниченной ответственностью "Т-Хелпер Клеточные Технологии" Материал стволовых клеток, композиции и способы применения
EP3472307A4 (en) 2016-06-15 2020-03-25 Ojai Energetics PBC Methods and compositions for potentiating stem cell therapies
JP2019527218A (ja) 2016-07-18 2019-09-26 ブレインストーム セル セラペウティクス リミテッド 筋萎縮性側索硬化症（ａｌｓ）を治療する方法
CN109790516A (zh) 2016-07-29 2019-05-21 罗廷灿 制备抑制癌细胞增殖的间充质干细胞的方法
WO2018038575A1 (ko) 2016-08-26 2018-03-01 연세대학교 산학협력단 중간엽 줄기세포 유래 분비 단백체를 포함하는 류마티스 관절염 치료용 약제학적 조성물 및 이를 이용한 치료 방법
EP3515474B1 (en) 2016-09-19 2026-03-04 Cambridge Innovation Technologies Consulting Limited Human asparaginase lacking glutaminase activity
US12161111B2 (en) 2016-09-23 2024-12-10 Peter Friedman Compositions and methods for treating citrus plants infected with bacteria and for promoting general agricultural health
US9980984B2 (en) 2016-10-13 2018-05-29 Kenneth Allen Pettine Treatment of inflammation of osteoarthritic knees with mesenchymal stem cells
IT201600109148A1 (it) 2016-10-28 2018-04-28 Pharmaexceed Srl Processo per isolare e liofilizzare vescicole extracellulari
US12053493B2 (en) 2016-11-03 2024-08-06 Exostem Biotec Ltd. Mesenchymal stem cells populations, their products, and use thereof
WO2018102696A1 (en) 2016-12-02 2018-06-07 Vmr Products Llc Vaporizer
US20180318356A1 (en) 2016-12-29 2018-11-08 Kenneth Allen Pettine Dermatological and cosmetic treatments using mesenchymal stem cells
US20190328792A1 (en) 2017-01-11 2019-10-31 Paracelsus Medizinische Privatuniversität Salzburg - Privatstiftung Mesenchymal stem cell-derived extracellular vesicles and their medical use
JP7015316B2 (ja) 2017-01-11 2022-02-02 ステムラボ・インコーポレイテッド ナノグを導入した羊水内胎児由来間葉系幹細胞から獲得したエクソソーム内に含まれた育毛促進用組成物の製造方法
JP2020505345A (ja) 2017-01-16 2020-02-20 セルズ フォー セルズ エセ．アー． 乏血小板血漿（ｐｐｐ）に封入された実質的に純粋な多能性間質細胞集団を含む組成物
US10987381B2 (en) 2017-01-27 2021-04-27 Neil Riordan Mesenchymal stem cells with enhanced efficacy in treatment of autoimmunity particularly rheumatoid arthritis
JP7225104B2 (ja) 2017-02-01 2023-02-20 ジービーエス グローバル バイオファーマ，インコーポレイテッド マスト細胞関連炎症障害又は好塩基球媒介炎症障害の治療のためのカンナビノイド含有複合混合物
WO2018150440A1 (en) 2017-02-16 2018-08-23 OCT Therapies and Research Private Limited Stem cell conditioned media for clinical and cosmetic applications
WO2018162696A1 (en) 2017-03-10 2018-09-13 Institut Pasteur Common genetic variations at the tcra-tcrd locus control thymic function in humans
US20180264043A1 (en) 2017-03-14 2018-09-20 Holding Pen, Llc Restoration of deteriorated tissue in the face or selected areas of the body with mesenchymal stem cells
US20180338866A1 (en) 2017-03-21 2018-11-29 Mohammad Ali Kharazmi Electroactive dressings
US20210254056A1 (en) 2017-05-05 2021-08-19 Camp4 Therapeutics Corporation Identification and targeted modulation of gene signaling networks
WO2018208670A1 (en) 2017-05-08 2018-11-15 Trustees Of Tufts College EXTRACELLULAR VESICLES COMPRISING MEMBRANE-TETHERED TGF-β, COMPOSITIONS AND METHODS OF USE THEREOF
EP3624817A4 (en) 2017-05-16 2021-05-19 Exostem Biotec Ltd. METHODS OF INHIBITING AGING AND TREATING AGING-RELATED DISORDERS
WO2018226758A2 (en) 2017-06-05 2018-12-13 The Regents Of The University Of California Methods for enhanced production and isolation of cell-derived vesicles and treatment of inflammation and neurological damage
CA3072562A1 (en) * 2017-08-15 2019-02-21 Children's Medical Center Corporation Purified mesenchymal stem cell exosomes and uses thereof
MX2020002085A (es) 2017-08-24 2020-07-13 Texas A & M Univ Sys Vesiculas extracelulares derivadas de celulas madre/estromales mesenquimaticas.
MA51649A (fr) * 2017-11-16 2020-09-23 Celularity Inc Culture de placenta pour isoler des exosomes
CA3085756A1 (en) 2017-12-14 2019-06-20 Mayo Foundation For Medical Education And Research Purified exosome products, method of making, and methods of using
WO2019126068A1 (en) 2017-12-20 2019-06-27 Cedars-Sinai Medical Center Engineered extracellular vesicles for enhanced tissue delivery
CN108042572A (zh) 2017-12-27 2018-05-18 北京多赢时代转化医学研究院 治疗白癜风的产品及其使用方法和应用
EP3740576A4 (en) 2018-01-18 2021-10-20 Advanced Regen Medical Technologies, LLC THERAPEUTIC COMPOSITIONS AND THEIR PREPARATION AND USE METHODS
JP2021511833A (ja) 2018-01-30 2021-05-13 ヒストジェン インコーポレイテッド 低酸素条件下にて培養された細胞に由来する細胞外小胞およびその使用方法
CN108456655A (zh) 2018-02-23 2018-08-28 深圳至博生物科技有限公司 间充质干细胞悬浮液及其制备方法与应用
WO2019169141A1 (en) 2018-02-28 2019-09-06 Lester Smith Medical Research Institute Production and use of extracellular vesicles
CN108498452A (zh) 2018-04-10 2018-09-07 上海交通大学医学院附属仁济医院 一种用于治疗勃起功能障碍的含干细胞可注射水凝胶及其制备方法
EP3773620A1 (en) 2018-04-10 2021-02-17 Brainstorm Cell Therapeutics Ltd. Cell-type specific exosomes and use thereof
EP3810271A4 (en) * 2018-04-30 2022-01-26 Children's Medical Center Corporation MESENCHYMAL STROMECELL EXOSOMES AND THEIR USE
US20210187032A1 (en) 2018-05-14 2021-06-24 Roosterbio, Inc. Methods and compositions related to extracellular material derived from hypertonic cell solutions
US12453743B2 (en) 2018-05-30 2025-10-28 Direct Biologics, Llc Mesenchymal stem cell (MSC) growth factor and extracellular vesicle preparation in frozen or powdered form and methods of use
EP3805383A4 (en) 2018-06-08 2022-08-10 KanonCure, Inc. ANTIFIBROSIS COMPOSITION, CELLS PRODUCING THESE CELLS AND CELL LAYER CONTAINING THESE CELLS
US20230142496A1 (en) 2018-06-18 2023-05-11 North Carolina State University Stem cell biomimetic nanoparticle therapeutic agents and uses thereof
US20210228643A1 (en) 2018-07-26 2021-07-29 Uniwersytet Jagiellonski N vivo delivery system of the genome dna modifying enzymes and the use thereof
US20200030253A1 (en) 2018-07-26 2020-01-30 Mohammad Ali Kharazmi Methods and compositions for treatment of body conditions
KR102163806B1 (ko) 2018-07-30 2020-10-07 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 피지분비 감소용 조성물
EP3829607A4 (en) 2018-08-02 2022-06-01 Histogen, Inc. Conditioned medium and extracellular matrix compositions and uses thereof
WO2020041725A1 (en) 2018-08-24 2020-02-27 University Of Delaware Extracellular vesicles as biomarkers and therapeutics for neuromuscular disorders
WO2020061408A1 (en) 2018-09-21 2020-03-26 Tarachon Llc Cartilage regeneration by synovial fluid-derived stem cells and their derivatives
WO2020069313A2 (en) 2018-09-28 2020-04-02 Henry Ford Health System Use of extracellular vesicles in combination with tissue plasminogen activator and/or thrombectomy to treat stroke
WO2020081859A1 (en) 2018-10-18 2020-04-23 Nantbio, Inc. Mesenchymal stem cell derived exosomes and methods
JOP20210170A1 (ar) 2018-12-26 2023-01-30 Direct Biologics Llc طرق وتركيبات لعلاج اضطرابات الجلد والشعر
WO2020142769A1 (en) 2019-01-04 2020-07-09 Kenneth Allen Pettine Isolation and use of autogenous platelet derived exosomes
CN109718392B (zh) 2019-01-18 2021-11-26 广州润虹医药科技股份有限公司 复合型医用敷料及其制备方法
BR112021014994A2 (pt) 2019-01-30 2021-10-05 Direct Biologics Llc Métodos e composições para o desenvolvimento de exossomos específicos e produtos de fator de crescimento
US20220195390A1 (en) 2019-02-07 2022-06-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preparing extracellular vesicles (ev) depletemedia
EP3920946A4 (en) 2019-02-07 2022-11-09 Direct Biologics LLC METHOD FOR TREATING OSTEOARTHRITIS USING A COMBINATION OF EXOSOMES OF MESENCHYMATE STEM CELLS, SYNOVIAL MESENCHYMATE STEM CELLS AND SCAFFOLDS
WO2020163705A1 (en) 2019-02-08 2020-08-13 Board Of Regents, The University Of Texas System Telomerase-containing exosomes for treatment of diseases associated with aging and age-related organ dysfunction
WO2020172270A1 (en) 2019-02-19 2020-08-27 Direct Biologics, Llc Acellular intravenous infusion including mesenchymal stem cell growth factors and exosomes
IT201900003639A1 (it) * 2019-03-13 2020-09-13 Evobiotech S R L Composizioni di vescicole extracellulari (EV) derivate da piante e loro usi
WO2020210363A1 (en) 2019-04-08 2020-10-15 Symbiocell Tech, Llc Treatment of microvascular disorders with mesenchymal stem cells and their exosomes
US10881693B2 (en) 2019-04-09 2021-01-05 Combangio, Inc. Processes for making and using a mesenchymal stem cell derived secretome
US20220202871A1 (en) 2019-04-29 2022-06-30 Direct Biologics, Llc Method for the treatment of periodontal disease using characterized mesenchymal stem cell growth factors and exosomes
KR102049505B1 (ko) 2019-05-14 2019-11-29 이장호 젖산탈수소효소 b 및 페록시좀 증식인자-활성화 수용체 감마 활성화인자 1-알파가 함유된 면역관용화된 세포외소포의 제조방법 및 이를 이용한 항암용 조성물
CN117384829A (zh) 2019-06-10 2024-01-12 布瑞克斯奥根株式会社 用于促进干细胞来源外泌体产生和增加干性的包含干扰素-γ的组合物
PH12021553167A1 (en) * 2019-06-19 2022-08-15 Celularity Inc Exosomes for disease treatment
WO2020261257A1 (en) 2019-06-26 2020-12-30 Technion Research And Development Foundation Limited Production of extracellular vesicles from stem cells
WO2021009660A1 (en) 2019-07-12 2021-01-21 Vasanthi Palanivel Composition and methods for improving thickness and receptivity of endometrial lining
EP3999083A4 (en) 2019-07-18 2023-07-26 Direct Biologics LLC Preparations comprising mesenchymal stem cells and cannabinoids and methods of their use
US20210169928A1 (en) 2019-07-22 2021-06-10 Erivan Bio, Llc Topical Exosome Compositions and Associated Methods
JP2022542953A (ja) 2019-07-31 2022-10-07 上▲海▼▲聖▼特佳健康科技▲発▼展有限公司 線維化、炎症、及び／又は老化疾患に対する治療薬
US11138804B2 (en) 2019-08-02 2021-10-05 Fmr Llc Intelligent smoothing of 3D alternative reality applications for secondary 2D viewing
JP7817160B2 (ja) 2019-11-15 2026-02-18 セクレトーム・セラピューティクス，インコーポレイテッド 心臓修復のための不死化心筋幹細胞
US20210169939A1 (en) 2019-12-04 2021-06-10 United Therapeutics Corporation Extracellular vesicles and their uses
AU2020398177A1 (en) 2019-12-05 2022-07-07 Board Of Regents, The University Of Texas System Exosomes-based therapy for liver fibrosis and other diseases associated with fibrosis
CN113134014B (zh) 2020-01-20 2023-09-26 医微细胞生物技术(广州)有限公司 囊泡在制备血友病药物中的应用
WO2021177473A1 (en) 2020-03-05 2021-09-10 Mvex Japan, Inc. Extracellular vesicle compositions and the use thereof in the treatment of skin conditions and in immune modulation
WO2021181399A1 (en) * 2020-03-12 2021-09-16 Exostem Biotec Ltd. Mesenchymal stromal cells and extracellular vesicles for treating viral infections, inflammation, and tissue fibrosis
US20230143893A1 (en) 2020-03-23 2023-05-11 Avem Holdings Llc Isolation and purification of exosomes for regenerative medicine
WO2021207282A2 (en) 2020-04-07 2021-10-14 Combangio, Inc. Lyophilized mesenchymal stem cell derived secretome and uses thereof
MX2022013301A (es) 2020-04-22 2023-02-14 Direct Biologics Llc Métodos y composiciones para tratar las afecciones inflamatorias asociadas con una enfermedad infecciosa.
KR102319735B1 (ko) 2020-04-28 2021-11-01 건국대학교 산학협력단 3차원 배양된 줄기세포로부터 세포외 소포체를 제조하는 방법
TW202146034A (zh) 2020-05-05 2021-12-16 美國商加速生物科學有限公司 包含有分泌蛋白體的藥學與化妝品組成物
BR112022026309A2 (pt) 2020-06-24 2023-01-17 Chameleon Biosciences Inc Vesículas extracelulares com moduladores imune
US20230248773A1 (en) 2020-07-09 2023-08-10 Exo Biologics Sa Extracellular Vesicles and Compositions Thereof
IL299634A (en) 2020-07-09 2023-03-01 Exo Biologics Sa A process for the production of protein-bound extracellular vesicles
JP2023537204A (ja) 2020-07-09 2023-08-31 エクソ バイオロジクス エスアー 間葉系ストローマ細胞由来の細胞外小胞（ｅｖ）および前記ｅｖを得るための方法
JP7691488B2 (ja) 2020-07-20 2025-06-11 ブレインストーム セル セラペウティクス リミテッド 肺疾患を治療するための方法及び組成物
JP2022043013A (ja) 2020-09-03 2022-03-15 学校法人自治医科大学 間葉系幹細胞又はそれに由来する前駆細胞の培養上清の浄化濃縮物、及びその製造方法
WO2022076419A1 (en) 2020-10-05 2022-04-14 Albert Einstein College Of Medicine Methods of treating viral infections with pirnas or extracellular vessicles released from neural stem cells or neural progenitor cells
US20220110970A1 (en) 2020-10-14 2022-04-14 The Texas A&M University System Engineered Extracellular Vesicle Delivery Systems and Uses Thereof
JP2023547728A (ja) 2020-11-06 2023-11-13 アーテック メディカル ジーエムビーエイチ 間葉系幹細胞由来の細胞外小胞およびアルファ－１アンチトリプシンを含むウイルス感染症治療用組成物
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
WO2022150696A1 (en) 2021-01-11 2022-07-14 United Therapeutics Corporation Ev for use in treating myocarditis
US20240148794A1 (en) 2021-02-12 2024-05-09 Modernatx, Inc. Lnp compositions comprising payloads for in vivo therapy
US20240197832A1 (en) 2021-05-24 2024-06-20 University Of Pittsburgh – Of The Commonwealth System Of Higher Education Methods and materials for treating a stroke
WO2022265864A2 (en) 2021-06-04 2022-12-22 The Brigham And Women’S Hospital, Inc Tim-3 modulates anti-tumor immunity by regulating inflammasome activation
AU2022289031A1 (en) 2021-06-09 2023-12-21 Allosource Tissue extracts and related methods
US20240307317A1 (en) 2021-06-17 2024-09-19 Thomas Malcolm Tailored hypoimmunenanovesicular delivery systems for cancer tumore, hereditary and infectious diseases
FR3124696B1 (fr) 2021-06-30 2025-03-14 Tbf Genie Tissulaire Materiau biologique imprégné de vesicules lipidiques
WO2023278883A1 (en) 2021-07-02 2023-01-05 Combangio, Inc. Processes for making and using a cellular fibronectin composition
JP7803499B2 (ja) 2021-07-06 2026-01-21 コングク ユニバーシティ インダストリアル コーオペレーション コーポレーション 幹細胞由来細胞外小胞体及びその用途
WO2023281524A1 (en) 2021-07-06 2023-01-12 Suma Kantipudi Placenta derived mesenchymal stromal cell secretome, process and uses thereof
US20240368701A1 (en) 2021-07-21 2024-11-07 Mercy Bioanalytics, Inc. Compositions and methods for cancer detection
WO2023021525A1 (en) 2021-08-16 2023-02-23 Lifecell International Pvt. Ltd A human amnion-chorion based wound dressing material and method thereof
WO2023024637A1 (zh) 2021-08-26 2023-03-02 中山大学 一种力学性囊泡的制备方法
KR102704051B1 (ko) 2021-08-30 2024-09-09 가톨릭대학교 산학협력단 세포 밖 소포체 함유 안표면 염증 질환 예방 또는 치료용 조성물
WO2023064555A1 (en) 2021-10-15 2023-04-20 The Board Of Trustees Of The Leland Stanford Junior University Cell-derived nanovesicles for in vivo transport and delivery of therapeutic materials
KR20230062452A (ko) 2021-10-29 2023-05-09 주식회사 씨케이엑소젠 연골 항상성 인자를 포함하는 엑소좀 및 이를 포함하는 골관절염 예방 또는 치료용 조성물
CA3237605A1 (en) 2021-11-12 2023-05-19 Darryl Raymond DAVIS Compositions of human heart derived extracellular vesicles and uses thereof
US20250032550A1 (en) 2021-11-16 2025-01-30 West Virginia University Board of Governors on behalf of West Virginia University A novel way for brain-specific delivery of molecules for the treatment of brain diseases
WO2023127645A1 (ja) 2021-12-28 2023-07-06 積水化学工業株式会社 エクソソーム、それを形成するための方法、及びそれを含有する組成物
WO2023123216A1 (zh) 2021-12-30 2023-07-06 中山大学 囊泡在制备治疗肺部疾病的药物中的应用
US20230226267A1 (en) 2022-01-19 2023-07-20 Semiflex Dome System Sp. Z.o.o. Dome catheter system for transcutaneous vacuum assisted closure of perianal or enterocutaneous abcesses and fistula tracts and method thereof
JP2025511272A (ja) 2022-03-29 2025-04-15 ダイレクト バイオロジクス エルエルシー Ｒｎａを含むセクレトームおよびその使用方法
WO2024192119A1 (en) 2023-03-14 2024-09-19 Direct Biologics, Llc Wound healing compositions and methods thereof
WO2024254540A2 (en) 2023-06-09 2024-12-12 Direct Biologics, Llc Treatment of amyotrophic lateral sclerosis with extracellular vesicle composition
CN121693335A (zh) 2023-06-09 2026-03-17 迪瑞克特生物制剂有限责任公司 使用细胞外囊泡组合物的复杂区域性疼痛综合征治疗
WO2025101663A1 (en) 2023-11-07 2025-05-15 Direct Biologics, Llc Extracellular vesicle composition for use in the treatment of graft-versus-host disease
WO2025101658A1 (en) 2023-11-07 2025-05-15 Direct Biologics, Llc Extracellular vesicle composition for use in the treatment of lumbar facet joint syndrome
WO2025101659A1 (en) 2023-11-07 2025-05-15 Direct Biologics, Llc Extracellular vesicle composition for use in the treatment of irradiated skin
TW202535437A (zh) 2023-11-07 2025-09-16 美商迪瑞克特生物製劑有限責任公司 使用胞外囊泡組合物之長新冠（ｌｏｎｇ ｃｏｖｉｄ）之治療
WO2025189128A1 (en) 2024-03-08 2025-09-12 Direct Biologics, Llc Treatment of infertility with extracellular vesicle composition
WO2025199333A1 (en) 2024-03-21 2025-09-25 Direct Biologics, Llc Treatment of ehlers-danlos syndrome with extracellular vesicle composition
WO2025226863A1 (en) 2024-04-24 2025-10-30 Direct Biologics, Llc Treatment of traumatic brain injury with extracellular vesicle composition
WO2025226866A1 (en) 2024-04-24 2025-10-30 Direct Biologics, Llc Bone marrow mesenchymal stem cell derived extracellular vesicles to improve perioral area and face fat graft retention
WO2025226276A1 (en) 2024-04-25 2025-10-30 Direct Biologics, Llc Treatment of fistula with bone marrow mesenchymal stem cell derived extracellular vesicles

Also Published As

Publication number Publication date
US20250277217A1 (en) 2025-09-04
AU2025220828A1 (en) 2025-09-11
WO2021216903A1 (en) 2021-10-28
JP2023523588A (ja) 2023-06-06
EP4138867A1 (en) 2023-03-01
US20230159932A1 (en) 2023-05-25
CN115843253A (zh) 2023-03-24
AU2021261384B2 (en) 2025-08-14
EP4138867A4 (en) 2024-05-01
US12570980B2 (en) 2026-03-10
KR20230004709A (ko) 2023-01-06
IL297563A (en) 2022-12-01
AU2021261384A1 (en) 2022-12-22
BR112022021445A2 (pt) 2023-01-10
CA3180973A1 (en) 2021-10-28

Similar Documents

Publication Publication Date Title
MX2022013301A (es) Métodos y composiciones para tratar las afecciones inflamatorias asociadas con una enfermedad infecciosa.
CO2022001210A2 (es) Conjugados de il-2 y métodos de uso para tratar enfermedades autoinmunes
CR20200334A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
MX2023000859A (es) Composiciones y metodos relacionados con agentes terapeuticos activables.
CL2020002915A1 (es) Composiciones para el tratamiento de condiciones de la piel
MX2021009259A (es) Conjugados de il-2 y metodos de uso del mismo.
MX2018009917A (es) Vacuna contra el virus del zika.
CO2022010330A2 (es) Dosificación de gamma-hidroxibutirato (ghb)
MX2020003995A (es) Nuevas moleculas de acido nucleico artificiales.
CR20200545A (es) Inhibidores magl
MX2025004075A (es) Vacunas para circovirus porcino tipo 3 (pcv3), y produccion y sus usos
MX2022001776A (es) Terapias de combinacion de inmuno oncologia con conjugados de il-2.
SV2011003888A (es) Compuestos que expanden las celulas madre hematopoieticas
CO2022000481A2 (es) Inhibidores de enzimas
MX2021012984A (es) Anticuerpos y metodos para el tratamiento de la infeccion por influenza a.
DOP2023000219A (es) Compuestos de tienopirrol
MX2024002913A (es) Anticuerpos anti-siglec-6 y metodos de uso de los mismos.
MX2020010932A (es) Enzimas quinureninasa humanas y sus usos.
CO2023004381A2 (es) Anticuerpos cd1a y su uso
CU20100056A7 (es) Método para inhibir la replicación del vih en células de mamíferos
AR119979A1 (es) Anticuerpos contra el factor de las células madre y métodos de uso de ellas
MX2022012618A (es) Aptameros para uso en el tratamiento de infecciones por coronavirus.
MX2023007643A (es) Ensamblaje in vitro de cápsides de anellovirus que encierran arn.
CL2023002602A1 (es) Uso de células madre mesenquimales sobreexpresoras de pacer para el tratamiento de enfermedades con origen y/o componente inflamatorio
CL2020000127A1 (es) Moduladores terapéuticos del modo inverso de la atp sintasa.